A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

  • Autoimmune Disorder
  • Rheumatoid Arthritis
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
Trial Identifier:

NCT02797769 GA30048

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This retrospective cohort study will analyze data from multiple large U.S. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying anti-rheumatic drugs (DMARDs) in real world patients with RA. Using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT02797769,GA30048 Trial Identifier
      Other Biologics, Tocilizumab Treatments
      Rheumatoid Arthritis Condition
      Official Title

      Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • At least 1 inpatient or 2 outpatient diagnoses of RA
      • Continuous medical/pharmacy coverage and full claims data available
      • At least 6 months of insurance plan enrollment prior to index date
      Exclusion Criteria
      • Nursing home residents
      • Human immunodeficiency virus (HIV)
      • Malignancy
      • Receipt of chemotherapy
      • End-stage renal disease, dialysis, or transplant
      • Use of rituximab
      • Recent cardiovascular event (includes MI, stroke, ACS, or HF) within 90 days prior to index date

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now